United Therapeutics Corporation (UTHR)
United Therapeutics: Is UTHR Stock Still A Buy At $400?
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF). The trial met its primary endpoint, and the treatment showed good tolerability with a safety profile consistent with prior Tyvaso studies.
United Therapeutics shares jump on positive lung disease study results
United Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TETON-2 study evaluating nebulized Tyvaso in patients with idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing significant improvements in lung function compared with placebo over a 52-week period.
United Therapeutics shares surge on successful late-stage lung disease study
Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.
United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET Company Participants C.Q. Deng - Corporate Participant Dewey Steadman - Head of Investor Relations Gil Golden - Senior VP & Chief Medical Officer James C.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $6.41 per share, missing the Zacks Consensus Estimate of $6.8 per share. This compares to earnings of $5.85 per share a year ago.
United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors
From a technical perspective, United Therapeutics (UTHR) is looking like an interesting pick, as it just reached a key level of support. UTHR recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
